AR095985A1 - Factores artificiales de transcripción y su uso para tratar la curación inadecuada de heridas oculares - Google Patents

Factores artificiales de transcripción y su uso para tratar la curación inadecuada de heridas oculares

Info

Publication number
AR095985A1
AR095985A1 ARP140101463A ARP140101463A AR095985A1 AR 095985 A1 AR095985 A1 AR 095985A1 AR P140101463 A ARP140101463 A AR P140101463A AR P140101463 A ARP140101463 A AR P140101463A AR 095985 A1 AR095985 A1 AR 095985A1
Authority
AR
Argentina
Prior art keywords
artificial transcription
transcription factors
treat
eye wounds
treatment
Prior art date
Application number
ARP140101463A
Other languages
English (en)
Original Assignee
Aliophtha Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aliophtha Ag filed Critical Aliophtha Ag
Publication of AR095985A1 publication Critical patent/AR095985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente se relaciona con factores artificiales de transcripción que comprenden proteínas con dedos de cinc polidáctiles dirigidas a promotores de genes involucrados con la cicatrización inadecuada de heridas oculares. Dichos factores artificiales de transcripción son útiles para el tratamiento de trastornos retinianos fibrocontractivos, tales como gliosis epirretiniana, vítreo-retinopatía proliferativa, retinopatía diabética proliferativa y membrana epirretiniana, y para el tratamiento de fibroplasia asociada con cirugía de glaucoma. Reivindicación 3: El factor artificial de transcripción de acuerdo con la reivindicación 1 que comprende una proteína con dedos de cinc de una secuencia de proteínas seleccionada del grupo que consiste en ID SEC Nº 88 a 128.
ARP140101463A 2013-04-03 2014-04-01 Factores artificiales de transcripción y su uso para tratar la curación inadecuada de heridas oculares AR095985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13162203 2013-04-03

Publications (1)

Publication Number Publication Date
AR095985A1 true AR095985A1 (es) 2015-11-25

Family

ID=48044674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101463A AR095985A1 (es) 2013-04-03 2014-04-01 Factores artificiales de transcripción y su uso para tratar la curación inadecuada de heridas oculares

Country Status (6)

Country Link
US (1) US20160039892A1 (es)
EP (1) EP2981548A1 (es)
JP (1) JP2016516749A (es)
AR (1) AR095985A1 (es)
TW (1) TW201441249A (es)
WO (1) WO2014161886A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005003315A2 (en) * 2003-07-01 2005-01-13 Allele Biotechnology & Pharmaceuticals, Inc. Compositions and methods for peptide-assisted transfection
WO2008063113A1 (en) * 2006-11-20 2008-05-29 Cepep Iii Ab Cell -penetrating peptides and constructs containing them consisting 15-25 amino acids of tumor supressor protein p14arf or p19arf
KR101095841B1 (ko) * 2009-02-19 2011-12-21 주식회사 나이벡 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도

Also Published As

Publication number Publication date
TW201441249A (zh) 2014-11-01
JP2016516749A (ja) 2016-06-09
WO2014161886A1 (en) 2014-10-09
US20160039892A1 (en) 2016-02-11
EP2981548A1 (en) 2016-02-10

Similar Documents

Publication Publication Date Title
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
BR112015024605A2 (pt) sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
WO2013126838A3 (en) Devices and methods for improving vision using laser photomiosis
BR112014008759A2 (pt) tratamento de doença ocular
AR081361A1 (es) Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
CO2017012454A2 (es) Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia
CO7131381A2 (es) Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto
UY37636A (es) Terapia génica para el tratamiento de retinitis pigmentosa ligada a cngb1
BR112014017161A8 (pt) dispositivo de oclusão implantável, método de fazer um dispositivo de oclusão implantável, dispositivo para limitar o fluxo de fluido e método para ocluir um lúmen num tecido corporal
CO2017005404A2 (es) Anticuerpos contra il-6
BR112017020132A2 (pt) métodos para promover o crescimento capilar ou prevenir a perda de cabelo em um indivíduo e para preparar uma composição, e, composição
EA201490531A1 (ru) Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции
BR112012013303A2 (pt) composições farmacêuticas e respectivos usos
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
EA201800265A1 (ru) Композиция регулятора роста растений с синергетическим эффектом
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
AU2018236629A8 (en) Hydrogel patch
CY1120003T1 (el) Αντιμικροβιακη πρωτεϊνη
AR092736A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r
CL2021003045A1 (es) Tratamiento de la disfunción sistólica
CO2021015265A2 (es) Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares
NZ729181A (en) Treatment of disease with poly-n-acetylglucosamine nanofibers
MX2017004520A (es) Composiciones para tratar heridas.
EA201990752A1 (ru) Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы
BR112023003834A2 (pt) Genes rpgrorf15 otimizados por códon e usos dos mesmos

Legal Events

Date Code Title Description
FB Suspension of granting procedure